Cargando…

Ion channels and pain in Fabry disease

Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. One prominent feature of Fabry...

Descripción completa

Detalles Bibliográficos
Autores principales: Weissmann, Carina, Albanese, Adriana A, Contreras, Natalia E, Gobetto, María N, Castellanos, Libia C Salinas, Uchitel, Osvaldo D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299890/
https://www.ncbi.nlm.nih.gov/pubmed/34284652
http://dx.doi.org/10.1177/17448069211033172
_version_ 1783726353406754816
author Weissmann, Carina
Albanese, Adriana A
Contreras, Natalia E
Gobetto, María N
Castellanos, Libia C Salinas
Uchitel, Osvaldo D
author_facet Weissmann, Carina
Albanese, Adriana A
Contreras, Natalia E
Gobetto, María N
Castellanos, Libia C Salinas
Uchitel, Osvaldo D
author_sort Weissmann, Carina
collection PubMed
description Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. One prominent feature of Fabry disease is neuropathic pain. Accumulation of Gb3 has been documented in dorsal root ganglia (DRG) as well as other neurons, and has lately been associated with the mechanism of pain though the pathophysiology is still unclear. Small fiber (SF) neuropathy in FD differs from other entities in several aspects related to the perception of pain, alteration of fibers as well as drug therapies used in the practice with patients, with therapies far from satisfying. In order to develop better treatments, more information on the underlying mechanisms of pain is needed. Research in neuropathy has gained momentum from the development of preclinical models where different aspects of pain can be modelled and further analyzed. This review aims at describing the different in vitro and FD animal models that have been used so far, as well as some of the insights gained from their use. We focus especially in recent findings associated with ion channel alterations -that apart from the vascular alterations-, could provide targets for improved therapies in pain.
format Online
Article
Text
id pubmed-8299890
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82998902021-08-06 Ion channels and pain in Fabry disease Weissmann, Carina Albanese, Adriana A Contreras, Natalia E Gobetto, María N Castellanos, Libia C Salinas Uchitel, Osvaldo D Mol Pain Review Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal α-galactosidase A (α-Gal A) activity which results in progressive accumulation of globotriaosylceramide (Gb3) and related metabolites. One prominent feature of Fabry disease is neuropathic pain. Accumulation of Gb3 has been documented in dorsal root ganglia (DRG) as well as other neurons, and has lately been associated with the mechanism of pain though the pathophysiology is still unclear. Small fiber (SF) neuropathy in FD differs from other entities in several aspects related to the perception of pain, alteration of fibers as well as drug therapies used in the practice with patients, with therapies far from satisfying. In order to develop better treatments, more information on the underlying mechanisms of pain is needed. Research in neuropathy has gained momentum from the development of preclinical models where different aspects of pain can be modelled and further analyzed. This review aims at describing the different in vitro and FD animal models that have been used so far, as well as some of the insights gained from their use. We focus especially in recent findings associated with ion channel alterations -that apart from the vascular alterations-, could provide targets for improved therapies in pain. SAGE Publications 2021-07-20 /pmc/articles/PMC8299890/ /pubmed/34284652 http://dx.doi.org/10.1177/17448069211033172 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Weissmann, Carina
Albanese, Adriana A
Contreras, Natalia E
Gobetto, María N
Castellanos, Libia C Salinas
Uchitel, Osvaldo D
Ion channels and pain in Fabry disease
title Ion channels and pain in Fabry disease
title_full Ion channels and pain in Fabry disease
title_fullStr Ion channels and pain in Fabry disease
title_full_unstemmed Ion channels and pain in Fabry disease
title_short Ion channels and pain in Fabry disease
title_sort ion channels and pain in fabry disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299890/
https://www.ncbi.nlm.nih.gov/pubmed/34284652
http://dx.doi.org/10.1177/17448069211033172
work_keys_str_mv AT weissmanncarina ionchannelsandpaininfabrydisease
AT albaneseadrianaa ionchannelsandpaininfabrydisease
AT contrerasnataliae ionchannelsandpaininfabrydisease
AT gobettomarian ionchannelsandpaininfabrydisease
AT castellanoslibiacsalinas ionchannelsandpaininfabrydisease
AT uchitelosvaldod ionchannelsandpaininfabrydisease